|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Morris M, Eifel PJ, Lu J, Grigsby PW,
Levenback C, Stevens RE, Rotman M, Gershenson DM and Mutch DG:
Pelvic radiation with concurrent chemotherapy compared with pelvic
and para-aortic radiation for high-risk cervical cancer. N Engl J
Med. 340:1137–1143. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Green JA, Kirwan JM, Tierney JF, Symonds
P, Fresco L, Collingwood M and Williams CJ: Survival and recurrence
after concomitant chemotherapy and radiotherapy for cancer of the
uterine cervix: A systematic review and meta-analysis. Lancet.
358:781–786. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Benedet JL, Odicino F, Maisonneuve P,
Beller U, Creasman WT, Heintz AP, Ngan HY and Pecorelli S:
Carcinoma of the cervix uteri. Int J Gynaecol Obstet. 83 Suppl
1:S41–S78. 2003. View Article : Google Scholar
|
|
5
|
Mabuchi S, Isohashi F, Yoshioka Y, Temma
K, Takeda T, Yamamoto T, Enomoto T, Morishige K, Inoue T and Kimura
T: Prognostic factors for survival in patients with recurrent
cervical cancer previously treated with radiotherapy. Int J Gynecol
Cancer. 20:834–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Waggoner SE: Cervical cancer. Lancet.
361:2217–2225. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Legge F, Chiantera V, Macchia G, Fagotti
A, Fanfani F, Ercoli A, Gallotta V, Morganti AG, Valentini V,
Scambia G and Ferrandina G: Clinical outcome of recurrent locally
advanced cervical cancer (LACC) submitted to primary multimodality
therapies. Gynecol Oncol. 138:83–88. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kosmas C, Mylonakis N, Tsakonas G, Vorgias
G, Karvounis N, Tsavaris N, Daladimos T, Kalinoglou N, Malamos N,
Akrivos T and Karabelis A: Evaluation of the
paclitaxel-ifosfamide-cisplatin (TIP) combination in relapsed
and/or metastatic cervical cancer. Br J Cancer. 101:1059–1065.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Benjapibal M, Thirapakawong C,
Leelaphatanadit C, Therasakvichya S and Inthasorn P: A pilot phase
II study of capecitabine plus cisplatin in the treatment of
recurrent carcinoma of the uterine cervix. Oncology. 72:33–38.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Borcoman E and Le Tourneau C:
Pembrolizumab in cervical cancer: Latest evidence and clinical
usefulness. Ther Adv Med Oncol. 9:431–439. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dallas NA, Fan F, Gray MJ, Van Buren G II,
Lim SJ, Xia L and Ellis LM: Functional significance of vascular
endothelial growth factor receptors on gastrointestinal cancer
cells. Cancer Metastasis Rev. 26:433–441. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Loncaster JA, Cooper RA, Logue JP,
Davidson SE, Hunter RD and West CM: Vascular endothelial growth
factor (VEGF) expression is a prognostic factor for radiotherapy
outcome in advanced carcinoma of the cervix. Br J Cancer.
83:620–625. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee IJ, Park KR, Lee KK, Song JS, Lee KG,
Lee JY, Cha DS, Choi HI, Kim DH and Deung YK: Prognostic value of
vascular endothelial growth factor in Stage IB carcinoma of the
uterine cervix. Int J Radiat Oncol Biol Phys. 54:768–779. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bachtiary B, Selzer E, Knocke TH, Pötter R
and Obermair A: Serum VEGF levels in patients undergoing primary
radiotherapy for cervical cancer: Impact on progression-free
survival. Cancer Lett. 179:197–203. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cheng WF, Chen CA, Lee CN, Wei LH, Hsieh
FJ and Hsieh CY: Vascular endothelial growth factor and prognosis
of cervical carcinoma. Obstet Gynecol. 96:721–726. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Iwasaki K, Yabushita H, Ueno T and
Wakatsuki A: Role of hypoxia-inducible factor-1α, carbonic
anhydrase-IX, glucose transporter-1 and vascular endothelial growth
factor associated with lymph node metastasis and recurrence in
patients with locally advanced cervical cancer. Oncol Lett.
10:1970–1978. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang J, Liu J, Zhu C, He J, Chen J, Liang
Y, Yang F, Wu X and Ma X: Prognostic role of vascular endothelial
growth factor in cervical cancer: A meta-analysis. Oncotarget.
8:24797–24803. 2017.PubMed/NCBI
|
|
18
|
Tewari KS, Sill MW, Long HJ III, Penson
RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao
MM, et al: Improved survival with bevacizumab in advanced cervical
cancer. N Engl J Med. 370:734–743. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schefter T, Winter K, Kwon JS, Stuhr K,
Balaraj K, Yaremko BP, Small W Jr, Sause W and Gaffney D: Radiation
Therapy Oncology Group (RTOG): RTOG 0417: efficacy of bevacizumab
in combination with definitive radiation therapy and cisplatin
chemotherapy in untreated patients with locally advanced cervical
carcinoma. Int J Radiat Oncol Biol Phys. 88:101–105. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cooke SL, Temple J, Macarthur S, Zahra MA,
Tan LT, Crawford RA, Ng CK, Jimenez-Linan M, Sala E and Brenton JD:
Intra-tumour genetic heterogeneity and poor chemoradiotherapy
response in cervical cancer. Br J Cancer. 104:361–368. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gorski DH, Beckett MA, Jaskowiak NT,
Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM,
Kufe DW and Weichselbaum RR: Blockage of the vascular endothelial
growth factor stress response increases the antitumor effects of
ionizing radiation. Cancer Res. 59:3374–3378. 1999.PubMed/NCBI
|
|
22
|
Moeller BJ, Cao Y, Li CY and Dewhirst MW:
Radiation activates HIF-1 to regulate vascular radiosensitivity in
tumors: Role of reoxygenation, free radicals, and stress granules.
Cancer Cell. 5:429–441. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rey S, Schito L, Koritzinsky M and Wouters
BG: Molecular targeting of hypoxia in radiotherapy. Adv Drug Deliv
Rev. 15:45–62. 2017. View Article : Google Scholar
|
|
24
|
Jiang BH, Agani F, Passaniti A and Semenza
GL: V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1)
and transcription of genes encoding vascular endothelial growth
factor and enolase 1: Involvement of HIF-1 in tumor progression.
Cancer Res. 57:5328–5335. 1997.PubMed/NCBI
|
|
25
|
Fu Z, Chen D, Cheng H and Wang F:
Hypoxia-inducible factor-1α protects cervical carcinoma cells from
apoptosis induced by radiation via modulation of vascular
endothelial growth factor and p53 under hypoxia. Med Sci Monit.
21:318–325. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dewhirst MW, Cao Y and Moeller B: Cycling
hypoxia and free radicals regulate angiogenesis and radiotherapy
response. Nat Rev Cancer. 8:425–437. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Burri P, Djonov V, Aebersold DM, Lindel K,
Studer U, Altermatt HJ, Mazzucchelli L, Greiner RH and Gruber G:
Significant correlation of hypoxia-inducible factor-1alpha with
treatment outcome in cervical cancer treated with radical
radiotherapy. Int J Radiat Oncol Biol Phys. 56:494–501. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chu TY, Yang JT, Huang TH and Liu HW:
Crosstalk with cancer-associated fibroblasts increases the growth
and radiation survival of cervical cancer cells. Radiat Res.
181:540–547. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Symonds RP, Gourley C, Davidson S, Carty
K, McCartney E, Rai D, Banerjee S, Jackson D, Lord R, McCormack M,
et al: Cediranib combined with carboplatin and paclitaxel in
patients with metastatic or recurrent cervical cancer (CIRCCa): A
randomised, double-blind, placebo-controlled phase 2 trial. Lancet
Oncol. 16:1515–1524. 2015. View Article : Google Scholar : PubMed/NCBI
|
